SONIC HEALTHCARE LIMITED (SHL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SHL

SHL - SONIC HEALTHCARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 3.24
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and imaging services to medical practitioners, hospitals, community health services, and their collective patients. It was first listed in 1987.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$20.58

25 Jun
2026

0.720

OPEN

$20.12

3.63%

HIGH

$20.81

2,230,300

LOW

$20.01

TARGET
$23.584 14.6% upside
Franking for last dividend paid out: 60%
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . EBO . HLS . IDX . M7T . MPL . MVF . NHF . RHC .
FNARENA'S MARKET CONSENSUS FORECASTS
SHL: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 123.1 123.7 xxx
DPS (cps) xxx 108.0 107.6 xxx
EPS Growth xxx 15.1% 0.5% xxx
DPS Growth xxx 0.9% - 0.4% xxx
PE Ratio xxx N/A 15.8 xxx
Dividend Yield xxx N/A 5.5% xxx
Div Pay Ratio(%) xxx 87.7% 87.0% xxx

Dividend yield today if purchased 3 years ago: 3.48%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 5.53

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 02/09 - ex-div 63.00c (franking 60%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx123.1
DPS All xxxxxxxxxxxxxxx108.0
Sales/Revenue xxxxxxxxxxxxxxx10,949.8 M
Book Value Per Share xxxxxxxxxxxxxxx1,687.5
Net Operating Cash Flow xxxxxxxxxxxxxxx1,405.5 M
Net Profit Margin xxxxxxxxxxxxxxx5.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx7.30 %
Return on Invested Capital xxxxxxxxxxxxxxx4.60 %
Return on Assets xxxxxxxxxxxxxxx3.64 %
Return on Equity xxxxxxxxxxxxxxx7.30 %
Return on Total Capital xxxxxxxxxxxxxxx7.77 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx240.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx742 M
Long Term Debt xxxxxxxxxxxxxxx5,097 M
Total Debt xxxxxxxxxxxxxxx5,840 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx654 M
Price To Book Value xxxxxxxxxxxxxxx1.23

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx735.6 M
Capex % of Sales xxxxxxxxxxxxxxx6.72 %
Cost of Goods Sold xxxxxxxxxxxxxxx7,922 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,942 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx227 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

03/06/2026

1

Buy

$28.75

39.70%

Bell Potter notes pathology activity continues to track below long-term growth averages.

Recent trends partly reflect tighter reimbursement criteria for vitamin B12 and urine MCS testing, as well as the normalisation of three-gene carrier screening volumes, the analysts explain.

The broker highlights Medicare Benefits Schedule (MBS) data does not capture much of Sonic Healthcare's domestic organic growth.

The analysts explain this growth is driven by private sector activity including government contracts, clinical trials, Department of Veterans' Affairs testing, corporate services and privately billed pathology work.

Unchanged Buy rating and $28.75 target.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 109.00 cents and EPS of 129.10 cents.
Bell Potter forecasts a full year FY27 dividend of 111.00 cents and EPS of 141.90 cents.

Morgan Stanley

xx/xx/xxxx

5

xxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxx xx xxxxxxxxxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

17/06/2026

3

Neutral

$22.30

8.36%

Jarden maintains a Neutral rating for Sonic Healthcare with its target price increased to $22.30 following the completion of a strategic sale and leaseback transaction for the Bowen Hills Laboratory.

The asset divestment generated immediate cash proceeds of $445m under a 20-year triple-net lease arrangement to substantially improve short-term cash flow optimisation paths.

Capital management parameters track the utilisation of unbooked accumulated capital losses to reduce transaction tax liabilities while systematically lowering overall gearing ratios.

The analyst notes near-term diluted earnings per share face minor negative adjustments to account for incremental depreciation expansions and higher embedded lease interest expenses.

The investment thesis balances these capital management benefits against ongoing global funding pressures and regulatory reimbursement headwinds across prominent European and domestic pathologies.

FORECAST
Jarden forecasts a full year FY26 dividend of 108.00 cents and EPS of 128.60 cents.
Jarden forecasts a full year FY27 dividend of 110.00 cents and EPS of 119.50 cents.
Access Extra Coverage Research History >

SHL STOCK CHART

FNArena News on SHL

Latest Healthcare services News

1
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
2
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
3
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals
4
Funding Overhang Weighs On Ramsay’s Rebound

Jun 10 2021 - Australia
5
Treasure Chest: More Pfizer Growth For Ebos Group

May 24 2021 - Treasure Chest
6
Treasure Chest: Demand Pumps Ramsay Health

Mar 03 2021 - Treasure Chest
7
Healius Enjoying Testing Times

Dec 11 2020 - Australia
8
The First Connection

Dec 10 2020 - Weekly Reports
9
Subdued Recovery For Ramsay Health Care

Nov 16 2020 - Australia
10
Recovery Underway For Sonic Healthcare

Jun 25 2020 - Australia